Pfizer And BioNTech Sell Millions of COVID-19 Vaccines to U.S. Government

Pfizer Inc. and BioNTech SE today announced that the U.S. government had purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty).

These vaccine doses are expected to be delivered from October 2021 through April 2022.

This purchase brings the total number of doses to be supplied by the companies to the U.S. government under its existing supply agreement to 500 million.

In a previous, separate announcement on June 10, 2021, Pfizer and BioNTech shared plans to provide the U.S. government with 500 million doses of the companies’ COVID-19 vaccine for donation to the world’s poorest nations.

“It has been our consistent goal to supply as many doses of our COVID-19 vaccine as possible to people around the world to help bring an end to this pandemic,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “We are honored to support the U.S. and more than 100 countries in their continuing vaccination programs.”

The companies expect to deliver 110 million of the additional doses by December 31, 2021, with the remaining 90 million doses to be delivered no later than April 30, 2022. The U.S. government also has the option to acquire an updated version of the vaccine to address potential variants and new formulations of the vaccine, if available and authorized.

The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) has not been approved or licensed by the U.S. Food and Drug Administration (FDA). Still, the FDA has authorized emergency use under an Emergency Use Authorization to prevent COVID-19 caused by the SARS-CoV-2 coronavirus for use in individuals 12 years of age and older.